KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Restructuring Costs: 2009-2016

Historic Restructuring Costs for Teva Pharmaceutical Industries (TEVA) over the last 8 years, with Dec 2016 value amounting to $699.0 million.

  • Teva Pharmaceutical Industries' Restructuring Costs rose 234.15% to $550,000.0 billion in Q3 2017 from the same period last year, while for Sep 2017 it was $969,000.5 billion, marking a year-over-year increase of 220.86%. This contributed to the annual value of $699.0 million for FY2016, which is 38.20% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Restructuring Costs of $699.0 million as of FY2016, which was down 38.20% from $1.1 billion recorded in FY2015.
  • Over the past 5 years, Teva Pharmaceutical Industries' Restructuring Costs peaked at $1.3 billion during FY2012, and registered a low of $650.0 million during FY2014.
  • For the 3-year period, Teva Pharmaceutical Industries' Restructuring Costs averaged around $826.7 million, with its median value being $699.0 million (2016).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Restructuring Costs soared by 74.00% in 2015, and later tumbled by 38.20% in 2016.
  • Over the past 5 years, Teva Pharmaceutical Industries' Restructuring Costs (Yearly) stood at $1.3 billion in 2012, then crashed by 37.41% to $788.0 million in 2013, then decreased by 17.51% to $650.0 million in 2014, then skyrocketed by 74.00% to $1.1 billion in 2015, then slumped by 38.20% to $699.0 million in 2016.